<table>
<thead>
<tr>
<th>Award Mechanism</th>
<th>Eligibility</th>
<th>Key Mechanism Elements</th>
<th>Funding</th>
<th>Submission Deadline</th>
</tr>
</thead>
</table>
| Exploration – Hypothesis Development Award | Investigators at or above the level of postdoctoral fellow (or equivalent)  | • Supports the exploration of highly innovative, untested, potentially high-gain concepts, theories, paradigms, and/or methods that address an important problem relevant to one or more FY22 PCRP Overarching Challenges.  
• Provides investigators the opportunity to pursue serendipitous observations that may reveal entirely new avenues for investigation.  
• Presentation of preliminary data is strongly discouraged.  
• Reviewers will be blinded to the identity of the Principal Investigator (PI), collaborators, and their organization(s).  
• Clinical research and clinical trials are not allowed.  
• Must address at least one of the FY22 PCRP Overarching Challenges. | • The maximum allowable funding for the entire period of performance is $100,000 for direct costs.  
• Indirect costs may be proposed in accordance with the institution's negotiated rate agreement.  
• The maximum period of performance is 2 years. | Pre-Application (Letter of Intent [LOI]):  
June 2, 2022  
5:00 p.m. Eastern time  
Application:  
June 23, 2022  
11:59 p.m. Eastern time |
| Early Investigator Research Award         | By March 31, 2023, Postdoctoral PIs:  
- Must possess a doctoral degree (or equivalent)  
- Have 3 years or less of postdoctoral research experience (excluding clinical residency or clinical fellowship training)  | • Supports research opportunities focused on prostate cancer for individuals in the early stages of their careers.  
• PIs must have a designated mentor who is an experienced prostate cancer researcher.  
• Must include a Researcher Development Plan articulating an individualized strategy for acquiring necessary skills, competence, and expertise to complete the project and foster the PI’s career development.  
• Must address at least one of the FY22 PCRP Overarching Challenges. | • The maximum allowable funding for the entire period of performance is $300,000 for direct costs.  
• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.  
• The maximum period of performance is 2 years. | Pre-Application (LOI):  
July 7, 2022  
5:00 p.m. Eastern time  
Application:  
July 28, 2022  
11:59 p.m. Eastern time  
Letters of Recommendation:  
August 2, 2022  
5:00 p.m. Eastern time |
<table>
<thead>
<tr>
<th>Award Mechanism</th>
<th>Eligibility</th>
<th>Key Mechanism Elements</th>
<th>Funding</th>
<th>Submission Deadline</th>
</tr>
</thead>
</table>
| Physician Research Award | At the time of application submission, the PI must be either:  
- In the last year of an accredited medical residency or medical fellowship program  
- Within 5 years of having initiated a faculty appointment (including Instructor positions) | • Supports a mentored research experience to prepare physicians with clinical duties for careers in prostate cancer research.  
• PIs must demonstrate a commitment to a career at the forefront of prostate cancer research and clinical practice.  
• PIs must have a designated mentor with an established research program in prostate cancer.  
• Applications are strongly encouraged to demonstrate protection of at least 40% of the PI’s time for prostate cancer research (not required to be exclusive to this award).  
• Must include a Researcher Development Plan articulating an individualized strategy for acquiring the necessary skills, competence, and expertise to complete the project and foster the PI's career development.  
• Must address at least one of the FY22 PCRP Overarching Challenges. | • The maximum allowable funding for the entire period of performance is **$750,000** for direct costs.  
• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.  
• The maximum period of performance is **4** years. | Pre-Application (LOI):  
July 7, 2022  
5:00 p.m. Eastern time  
Application:  
July 28, 2022  
11:59 p.m. Eastern time  
Letters of Recommendation:  
August 2, 2022  
5:00 p.m. Eastern time |
<table>
<thead>
<tr>
<th>Award Mechanism</th>
<th>Eligibility</th>
<th>Key Mechanism Elements</th>
<th>Funding</th>
<th>Submission Deadline</th>
</tr>
</thead>
</table>
| Translational Science Award     | Independent investigators at all levels  | • Supports advanced translational research that will foster transformation of promising ideas in prostate cancer into clinical applications, ultimately providing a solution to one or more of the FY22 PCRP Overarching Challenges.  
  • Translational research may be defined as an integration of basic science and clinical observations, including a reciprocal flow of ideas and information from bench to bedside and/or bedside to bench.  
  • Supports a broad range of translational studies such as:  
    o Advanced translation of results from animal studies to applications with human samples/cohorts  
    o Late-stage preclinical work leading to/preparing for a clinical trial, e.g., Investigational New Drug application submission  
    o Correlative studies that are associated with an open/ongoing or completed clinical trial, e.g., projects that utilize biospecimens from clinical trial to improve clinical management of prostate cancer and/or define new areas of research  
    o Projects that develop endpoints for clinical trials  
  • Preliminary data to support the scientific rationale and feasibility of the research approaches are required. The inclusion of additional preliminary data to support the clinical relevance of the idea is strongly encouraged.  
  • Clinical trials are not allowed.  
  • Partnering PI Option: Allows two PIs, termed the Initiating and Partnering PIs, to collaborate on a single application. Collaborations between basic science and clinical researchers are highly encouraged.  
  • Must address at least one of the FY22 PCRP Overarching Challenges. | • The maximum allowable funding for the entire period of performance is $900,000 for direct costs.  
  • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.  
  • The maximum period of performance is 3 years. | Pre-Application (LOI):  
  August 4, 2022  
  5:00 p.m. Eastern time  
  Application:  
  August 25, 2022  
  11:59 p.m. Eastern time |

**Grants.gov Funding Opportunity Number:** W81XWH-22-PCRP-TSA

**Go to:**  
- Program Announcement  
- General Application Instructions
<table>
<thead>
<tr>
<th>Award Mechanism</th>
<th>Eligibility</th>
<th>Key Mechanism Elements</th>
<th>Funding</th>
<th>Submission Deadline</th>
</tr>
</thead>
</table>
| Health Disparity Research Award | Established Investigators: Independent investigators at all levels  
New Investigators: Investigators that meet the following criteria at the application submission deadline date:  
- Have the freedom to pursue individual aims without formal mentorship  
- Have not previously received a PCRP Health Disparity Research Award and/or Idea Development Award  
- Have either completed at least 3 years of postdoctoral training or fellowship or are within 10 years after completion of a terminal degree (excluding residency or family medical leave) | Supports research ideas that have the potential to make an important contribution to reducing and ultimately eliminating disparities in prostate cancer incidence, morbidity, and mortality.  
- Proposed projects must address one of the following health disparity focus areas: (1) biological contributors, (2) environmental factors, (3) social and cultural factors, or (4) access to healthcare.  
- Proposed projects may include basic, translational, or clinical research, including clinical trials.  
- Primary emphasis will be placed on the potential impact of the proposed work.  
- Preliminary data are encouraged, but not required.  
- Must address at least one of the FY22 PCRP Overarching Challenges. | The maximum allowable funding for the entire period of performance is **$900,000** for direct costs.  
- Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.  
- The maximum period of performance is **3 years**. | Pre-Application (LOI):  
August 4, 2022  
5:00 p.m. Eastern time  
Application:  
August 25, 2022  
11:59 p.m. Eastern time |
<table>
<thead>
<tr>
<th>Award Mechanism</th>
<th>Eligibility</th>
<th>Key Mechanism Elements</th>
<th>Funding</th>
<th>Submission Deadline</th>
</tr>
</thead>
<tbody>
<tr>
<td>Idea Development Award</td>
<td>Established Investigators: Independent investigators at all levels</td>
<td>• Supports new ideas that represent innovative, high-risk/high-gain approaches to prostate cancer research and have the potential to make an important contribution to one or more of the FY22 PCRP Overarching Challenges.</td>
<td>• The maximum allowable funding for the entire period of performance is $900,000 for direct costs.</td>
<td>Pre-Application (LOI): July 7, 2022 5:00 p.m. Eastern time</td>
</tr>
<tr>
<td>Go to:</td>
<td>New Investigators: Investigators that meet the following criteria at the application submission deadline date:</td>
<td>• Emphasis is equally placed on Innovation and Impact.</td>
<td>• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.</td>
<td>Application: July 28, 2022 11:59 p.m. Eastern time</td>
</tr>
<tr>
<td>• Program Announcement</td>
<td>• Have the freedom to pursue individual aims without formal mentorship</td>
<td>• Preliminary data are encouraged, but not required.</td>
<td>• The maximum period of performance is 3 years.</td>
<td></td>
</tr>
<tr>
<td>• General Application Instructions</td>
<td>• Have not previously received a PCRP Health Disparity Research Award and/or Idea Development Award</td>
<td>• Clinical trials are not allowed.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grants.gov Funding Opportunity Number: W81XWH-22-PCRP-IDA</td>
<td>• Have either completed at least 3 years of postdoctoral training or fellowship or are within 10 years after completion of a terminal degree (excluding residency or family medical leave)</td>
<td>• Multidisciplinary projects are encouraged, and multi-institutional projects are allowed.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Must address at least one of the FY22 PCRP Overarching Challenges.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Award Mechanism</td>
<td>Eligibility</td>
<td>Key Mechanism Elements</td>
<td>Funding</td>
<td>Submission Deadline</td>
</tr>
<tr>
<td>-----------------</td>
<td>-------------</td>
<td>------------------------</td>
<td>---------</td>
<td>---------------------</td>
</tr>
</tbody>
</table>
| Data Science Award | Independent investigators at all levels | • Supports research where quantitative and analytical approaches, processes, and/or systems are developed and/or used to obtain knowledge and insight from large and/or complex sets of prostate cancer data.  
• Applications may propose development of a new data-science-driven tool or apply an existing tool or method to gather and analyze information from large data sets with the intent of advancing prostate cancer research and patient care relative to the FY22 PCRP Overarching Challenges.  
• Research efforts must be built upon the logic, concepts, and methods of one or more of the following research areas as they pertain to prostate cancer:  
  o Computational biology  
  o Bioinformatics  
  o Artificial intelligence and machine learning  
  o Epidemiology  
  o Analysis of -omics data  
  o Medical imaging  
  o Digital pathology  
  o Analysis of clinically annotated datasets  
• Clinical research is allowed, but must be retrospective; prospective recruitment of human subjects and/or clinical trials is not allowed.  
• Presentation of preliminary data is strongly encouraged, but not required.  
• Partnering PI Option: Allows two PIs, termed the Initiating and Partnering PIs, to collaborate on a single application. Collaborations between data scientists and clinicians are highly encouraged. At least one of the submitting or partnering PIs must have expertise in prostate cancer basic and/or clinical research.  
• Must address at least one of the FY22 PCRP Overarching Challenges. | • The maximum allowable funding for the entire period of performance is **$1,000,000** for direct costs.  
• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.  
• The maximum period of performance is **3** years. | Pre-Application (LOI):  
August 4, 2022  
5:00 p.m. Eastern time  

Application:  
August 25, 2022  
11:59 p.m. Eastern time |